Comparison of the Quality of life in Patients with Early and Established Rheumatoid Arthritis

2020 ◽  
Author(s):  
Lyudmila Sizova
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Joint Pain ◽  
Disease Process ◽  
First Year ◽  
Functional Disorders ◽  
Physical Pain ◽  
Early Ra ◽  
Sf 36

Abstract Aim: To compare the quality of life (QOL) in patients with early rheumatoid arthritis (RA) against patients with established RA.Methods: The clinical study included 164 participants from Russia: 114 outpatients with early RA, and 50 outpatients with established RA. Assessment of QOL in RA patients detected impaired indicators of the HAQ, SF-36 questionnaires, QOL-RA Scale already during the first year of the disease.Results: The HAQ test found a comparable frequency of severe functional disorders in patients with early and established RA. According to the SF-36 questionnaire, patients with early RA suffered from physical pain than patients with established RA. The QOL-RA Scale demonstrated that patients with initial stages of the disease process had the lowest scores for the "arthritis" and "joint pain", and participants with established RA additionally and on the "health".Conclusions: A comparative study of the QOL in respondents with early and established RA has shown that patients have a decrease it already during the first year of the disease on many indicators, as patients with a long anamnesis, and even experience more pronounced physical pain. So, tested questionnaires can provide benefits for monitoring health status and comparison of the effectiveness of drugs and treatment methods.

Comparison of the quality of life in patients with early and long-term rheumatoid arthritis (Preprint)

2020 ◽  
Author(s):  
Lyudmila Sizova
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Life Quality ◽  
Correct Choice ◽  
First Year ◽  
Early Ra ◽  
Sf 36 ◽  
State Medical Academy

BACKGROUND The research interest is the study of the quality of life of patients with rheumatoid arthritis of different duration. OBJECTIVE The aim of study was to compare the quality of life in patients with early rheumatoid arthritis (RA) against patients with long-term RA. METHODS The study included 164 participants: 114 outpatients with early RA, and 50 outpatients with long-term RA. Assessment of life quality in patients with RA detected impaired parameters of the HAQ, SF-36, QOL-RA Scale already during the first year of the disease. RESULTS The HAQ test found a comparable frequency of severe functional disorders in patients with early and long-term RA. According to the SF-36 questionnaire, patients with early RA suffered from physical pain than patients with long-term RA. The QOL-RA Scale demonstrated that patients in the early stages of the disease, the lowest scores for the "arthritis" and "joint pain", and participants with long-term RA for "health" also. CONCLUSIONS Results indicated that these questionnaires may be used for scientific purposes to identify the most susceptible parameters of the quality of life and to provide benefits for monitoring health status and correct choice of drugs. CLINICALTRIAL The Scientific Council of the Orenburg State Medical Academy (currently the University) approved research in 2005 year (Protocol No. 5). All patients gave their written consent to participate in the scientific study.

scholarly journals Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study

2011 ◽  
Vol 39 (1) ◽  
pp. 63-72 ◽  
Author(s):  
VIBEKE STRAND ◽  
ANNE M. RENTZ ◽  
MARY A. CIFALDI ◽  
NAIJUN CHEN ◽  
SANJOY ROY ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Short Form ◽  
Health Related Quality ◽  
Link Type ◽  
Early Ra ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related

Objective.Rheumatoid arthritis (RA) is associated with significant impairments in health-related quality of life (HRQOL). We evaluated patient-reported outcomes including HRQOL outcomes following adalimumab plus methotrexate (MTX) therapy in patients with early RA.Methods.PREMIER was a phase III, multicenter, randomized, double-blind, active-comparator clinical trial in early RA. Patients aged ≥ 18 years were randomly assigned to receive adalimumab 40 mg every other week (eow) plus weekly MTX, weekly MTX, or adalimumab 40 mg eow for 104 weeks. American College of Rheumatology (ACR) criteria were used to evaluate clinical efficacy and response. Outcomes were assessed using the Health Assessment Questionnaire Disability Index (HAQ-DI), Short-Form 36 Health Survey (SF-36), Short-Form 6 Dimension (SF-6D), visual analog scale (VAS) assessments of global disease activity (patient’s global assessment; PtGA) and pain, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), and Health Utility Index Mark 3 (HUI-3).Results.Of 799 patients enrolled, 268 received adalimumab plus MTX, 257 received MTX monotherapy, and 274 received adalimumab monotherapy. Patients treated with adalimumab plus MTX demonstrated significant baseline to Week 104 improvements in HAQ-DI (p < 0.0001), SF-36 Physical Component Summary (p < 0.0001), 4 SF-36 domains [physical function (p < 0.0001), bodily pain (p <0.0001), vitality (p = 0.0139), role limitations-physical (p = 0.0005)], SF-6D (p = 0.0152), VAS-PtGA (p < 0.0001), VAS-pain (p < 0.0001), FACIT-F (p < 0.0001), and HUI-3 (p = 0.0034) scores versus patients treated with MTX monotherapy. Both SF-6D and HUI-3 were found to be sensitive preference-based measures for assessing the effects of treatment on multidimensional function. No clinically meaningful differences between adalimumab and MTX monotherapy groups were observed for most measures. For each measure, there was significant association between HRQOL improvement and ACR clinical response.Conclusion.Adalimumab plus MTX significantly improved physical functioning and HRQOL in patients with early RA over 2 years of treatment. (ClinicalTrials.gov identifier NCT00195663).

scholarly journals POS1455-HPR RELATIONSHIP BETWEEN PSYCHOLOGICAL FACTORS AND MEASURES OF RHEUMATOID ARTHRITIS ACTIVITY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1011.2-1011
Author(s):  
Y. Olyunin ◽  
V. Rybakova ◽  
E. Likhacheva ◽  
E. Nasonov
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Psychological Factors ◽  
Global Assessment ◽  
Activity Level ◽  
Anxiety And Depression ◽  
Tender Joint Count ◽  
Sf 36 ◽  
Patient Reported

Background:The patient-reported outcomes are important components of quantitative methods of rheumatoid arthritis (RA) activity assessment which are used to choose the appropriate drug therapy. The value of these parameters can be significantly affected not only by the inflammatory process, but also by the psychological characteristics of the patient and, in particular, by hardiness [1].Objectives:To study the relationship between psychological factors and signs of RA activity.Methods:Patients with RA who met the EULAR/ACR 2010 criteria, and observed at the V. A. Nasonova Research Institute of Rheumatology were included. Clinical examination was performed including patient global assessment (PGA), physician global assessment (PhGA), pain measurement on a visual analog scale, tender joint count (TJC), swollen joint count (SJC). The functional status was determined by HAQ, the quality of life – by SF-36 EQ-5D, the nature of pain – by painDETECT, the presence of anxiety and depression – by HADS. Patients also completed Hardiness Survey questionnaire to assess hardiness (HDS) and 3 components of the HDS – commitment (CMT), control (CT) and challenge (CLN). Disease activity was evaluated with DAS28, CDAI, and RAPID3. All patients signed informed consent to participate in the study. Analysis of the data was performed using Spearman’s rank test, Fisher exact test, qui-square and t-tests.Results:85 patients with RA were included. There were 69 women and 16 men. Mean age was 56.7±13.1 years, disease duration – 7.6±2.7 years. 72 patients were positive for rheumatoid factor, 75 – for anti-cyclic citrullinated peptide antibody. CDAI showed high activity in 15, moderate – in 37, low – in 30, and remission in 3 patients, DAS 28 – in 10, 55, 12, and 8, and RAPID3 – in 24, 25, 15, and 21, respectively. 24 patients had subclinically or clinically expressed anxiety and 15 –subclinically or clinically expressed depression (≥8 according to HADS). In 31 patients, the painDETECT questionnaire revealed possible or probable neuropathic pain. Mean HDS was 84.8±21.7, CMT – 38.9±9.2, CT – 29.4±8.6, CLN – 17.3±7.1. These values were comparable with the corresponding population data for this age group. There was a significant inverse correlation between HDS and RA activity measures, including SJC, TJC, DAS28 (p<0.05), pain, PGA, PhGA, CDAI, RAPID3, and HAQ (p<0.01). In addition, HDS and all its components positively correlated with quality of life, assessed by SF-36 and EQ-5D (p<0.01). In patients with subclinically and clinically expressed anxiety and depression, HDS, CMT, and CT were significantly lower than in patients without anxiety and depression (p<0.01), while the values of CLN in these groups did not differ significantly.Conclusion:The results of the present study suggest that low HDS may be one of the significant factors determining RA activity level because it does not allow patients to adapt adequately to a stressful situation produced by the disease.References:[1]Maddi SR. Am Psychol. 2008 Sep;63(6):563-4.Disclosure of Interests:None declared

Quality of life of osteoporotic patients attending rheumatology rehabilitation in-patient units

2012 ◽  
Vol 153 (33) ◽  
pp. 1314-1319
Author(s):  
Julianna Rozália Sallai ◽  
Gábor Héjj ◽  
István †Ratkó ◽  
Aniella Hunka ◽  
Ilona Márkus ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Low Back Pain ◽  
Back Pain ◽  
Chronic Low Back Pain ◽  
Poor Quality ◽  
Low Back ◽  
Life Data ◽  
Sf 36

There has been no report on demographic, social and quality of life data of osteoporotic patients attending rheumatology rehabilitation in-patient units in Hungary. Aim: The authors analyzed the data of osteoporotic patients treated in rheumatology rehabilitation departments as in-patients in four hospitals in Hungary. Methods: Demographic and social data were obtained by using a questionnaire developed by the authors, and quality of life was assessed with the use of the SF-36 questionnaire. The quality of life data of osteoporotic patients were compared to that obtained from patients with rheumatoid arthritis, osteoarthrosis and chronic low back pain who were treated in the same department at the same time. Results: Of the 253 patients who were asked to participate in the study, 211 patients filled out the questionnaires. 25.6% of the patients were male. 58% of the patients were younger than 60 years of age, and 40% of them were heavy physical workers earlier. More than 50% of the patients did not complete secondary school education, and only 6.7% of the patients had a per capita monthly income higher than 100 000 HUF. The quality of life of the osteoporotic patients assessed by SF-36 scored 34.7, which was significantly lower than that of the mean of the Hungarian population scoring 70–90. The SF-36 scores of osteoporotic patients were lower in all domains compared to the scores of patients with rheumatoid arthritis, osteoarthritis and low back pain, although the difference was significant only in the domain of physical activity. The affective role of patients with osteoporosis was significantly lower than those with rheumatoid arthritis and osteoarthritis. Conclusions: Osteoporotic patients attending in-patient rheumatology in-patient rehabilitation units in Hungary have poor quality of life comparable, even worse than that found in patients with rheumatoid arthritis, osteoarthritis and chronic low back pain. Orv. Hetil., 2012, 153, 1314–1319.

scholarly journals Twelve Weeks of Strengthening Exercise for Patients with Rheumatoid Arthritis: A Prospective Intervention Study

2020 ◽  
Vol 9 (9) ◽  
pp. 2792
Author(s):  
Bomi Sul ◽  
Kyoung Bo Lee ◽  
Young Bin Joo ◽  
Bo Young Hong ◽  
Joon-Sung Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Lower Limb ◽  
Exercise Group ◽  
Activity Level ◽  
Control Group ◽  
Intervention Period ◽  
Sf 36 ◽  
Strengthening Exercise

Rheumatoid arthritis (RA) patients may benefit from exercise for several reasons. However, whole-limb strengthening exercises for such patients remain poorly studied. We hypothesized that systemic strength training that includes the upper and lower extremities would improve strength per se and enhance the quality of life. Here, we investigated the effects of 12 weeks of upper- and lower-limb strengthening exercise on the strength and quality of life of RA patients using the International Classification of Functioning, Disability, and Health model. This was a prospective, interventional controlled trial. Forty female RA patients were recruited and assigned to two groups not based on willingness to exercise, with 20 patients in the exercise group and 20 in the control group. All patients in the exercise group received once-weekly training sessions of 60 min over 12 weeks. All participants were assessed before and after the 12-week intervention period. We measured the hand grip strength and isometric quadriceps contraction, the cross-sectional area of the rectus femoris (CSA-RF) (via ultrasonography), and performed the 30 s sit-to-stand test and the 6 min walk test (6MWT). We derived the Borg scale score after the 6MWT and assessed the extent of social participation and quality of life using a Korean version of the 36-Item Short Form Health Survey (SF-36). A total of 35 subjects completed the experiment (18 in the exercise group, 17 in the control group). After the 12-week intervention period, the lower-limb strength and the CSA-RF were significantly increased in the exercise group. The activity level did not change significantly in either group. The exercise group exhibited significant improvements in the SF-36 mental health domain scores. Thus, strengthening exercise is useful for patients with RA.

The Effect of Intravenous Golimumab on Health-related Quality of Life in Rheumatoid Arthritis: 24-week Results of the Phase III GO-FURTHER Trial

2014 ◽  
Vol 41 (6) ◽  
pp. 1067-1076 ◽  
Author(s):  
Clifton O. Bingham ◽  
Michael Weinblatt ◽  
Chenglong Han ◽  
Timothy A. Gathany ◽  
Lilianne Kim ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Physical Function ◽  
Phase Iii ◽  
Health Related Quality ◽  
Sf 36 ◽  
Related Quality ◽  
Health Related ◽  
Disease Effect

Objective.To evaluate the effects of intravenous (IV) golimumab 2 mg/kg + methotrexate (MTX) on patient-reported measures of health-related quality of life (HRQOL) in patients with active rheumatoid arthritis (RA) despite prior MTX therapy.Methods.In this randomized, multicenter, double-blind, placebo-controlled, phase III trial, adults with RA were randomly assigned to receive IV placebo (n = 197) or golimumab 2 mg/kg (n = 395) infusions at Week 0, Week 4, and every 8 weeks thereafter. All patients continued stable oral MTX (15–25 mg/wk). HRQOL assessments included Health Assessment Questionnaire-Disability Index (HAQ-DI; physical function), Medical Outcomes Study Short Form-36 questionnaire physical/mental component summary (SF-36 PCS/MCS) scores, EQ-5D assessment of current health state, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire, and disease effect on productivity [10-cm visual analog scale (VAS)].Results.Mean HAQ-DI improvements from baseline were significantly greater with golimumab + MTX than placebo + MTX at Week 14 and Week 24 (p < 0.001). Significantly greater improvements in all 8 individual SF-36 subscores and both the SF-36 PCS and MCS scores (p < 0.001) also accompanied golimumab + MTX therapy. Improved EQ-5D and EQ-5D VAS (p < 0.001) and FACIT-Fatigue (p < 0.001) scores were also observed for golimumab + MTX-treated patients at Week 12, Week 16, and Week 24, and greater proportions of golimumab + MTX-treated patients had clinically meaningful improvements in these measures. Greater reductions in disease effect on productivity were observed with golimumab + MTX versus placebo + MTX at Week 24 (p < 0.001). Improvements in physical function, HRQOL, fatigue, and productivity significantly correlated with disease activity improvement.Conclusion.In active RA, IV golimumab + MTX significantly improved physical function, HRQOL, fatigue, and productivity using multiple measurement tools; all correlated with improvements in disease activity (NCT00973479, EudraCT 2008-006064-11).

scholarly journals IMPACT OF DIFFERENT LEVELS OF DISEASE ACTIVITY IN PAINFUL PROFILE AND QUALITY OF LIFE IN PEOPLE WITH RHEUMATOID ARTHRITIS

2014 ◽  
Vol 2 (1) ◽  
Author(s):  
Selena Márcia Dubois Mendes ◽  
Bárbara Liliane Lôbo Queiroz ◽  
Larissa Vieira Santana ◽  
Abrahão Fontes Baptista ◽  
Mittermayer Barreto Santiago ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Pain Perception ◽  
Short Form ◽  
Care Service ◽  
Cross Sectional ◽  
Sf 36 ◽  
Different Levels

Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease with impact on increasing the morbidity and mortality rates. Different levels of disease activity (LDA) have been established, however, its impact on pain and quality of life have yet to be been evidenced. The aim of this study was to evaluate the relationship of different levels of disease activity on the painful profile and quality of life (QOL) of patients diagnosed with RA. This was a cross-sectional study, conducted in RA patients attending an Educational Outpatient Care Service in Salvador, Bahia, Brazil. The LDA was defined according to values of Erythrocyte Sedimentation Rate (ESR), Visual Analog Scale (VAS), and number of swollen and sore joints, according to the Disease Activity Score in 28 joints (DAS28). Types of pain were assessed using the Douleur Neuropathique en 4 questions (DN4). To evaluate QOL, the Short Form (36) Health Survey (SF-36) and Health Assessment Questionnaire (HAQ) were applied. The association between LDA, QOL and painful profile was verified using One Way-ANOVA and Bonferroni correction post-test. A high LAD was observed in 67.7% of the 96 patients  evaluated in this study. Pain sensation was reported by 94.8 % of participants with 40.6 % reporting it as nociceptive and 80.2% as intense. It was also observed that the higher LAD found the higher was the pain intensity reported (p=0.001) and lower QOL scores (p<0.001). Although the LDA did not correlate with the type of pain (p=0.611), it was correlated with the total score obtained in the QOL from the HAQ (p=0.001). The greatest impact on QOL evaluated through the SF-36 were physical (p<0.001) and functional capacity (p<0.001). In conclusion, RA patients who had high LDA reported more severe pain perception and obtained the lowest scores in the assessment of quality of life.

scholarly journals ASSOCIATION OF CLINICAL, PSYCHOEMOTIONAL STATUS AND THE PATHOGENETIC THERAPY WITH THE DEVELOPMENT OF REMISSION IN ADULT PATIENTS WITH JUVENILE RHEUMATOID ARTHRITIS

2018 ◽  
Vol 14 (1-2) ◽  
pp. 24-33
Author(s):  
M.B. Dzhus
Keyword(s):  
Quality Of Life ◽  
Rheumatoid Arthritis ◽  
Femoral Neck ◽  
Juvenile Rheumatoid Arthritis ◽  
Adult Patients ◽  
Group I ◽  
Sf 36 ◽  
Pathogenetic Therapy ◽  
Active Disease

Relevance. The study of the frequency of remission in adult patients  with JRA treated in accordance with the "Unified clinical protocol for medical care for patients with juvenile rheumatoid arthritis" is relevant. Objective. The aim of our study was to evaluate the association of the clinical, psycho-emotional state and the pathogenetic therapy with the development of remission in adult patients with JRA. Materials and methods. 168 adult patients with JRA were examined at the transition period of the health care and adolescents. A retrospective analysis of medical records was performed to evaluate clinical symptoms and laboratory data in childhood and evaluated the clinical status, duration of the disease, activity on the JADAS and DAS-28 scales, quality of life, depression and alexithymia by scales SF-36, PHQ-9, TAS- 20, bone mineral density and methods of treatment in childhood and in adulthood. Results. All patients were divided into 2 groups: Group I - 138 patients (82.1%) with active disease at the time of examination, and II group - 30 patients (17.9%) who achieved remission. Patients who achieved remission did not differ by age at the time of the study, although the prevalence of women (58.1%) in the I group was determined, compared with 31.0% in the II group. Patients in both groups did not differ in height, however, patients with remission had a greater body weight (p <0.01) and BMI (p <0.01). There were no differences between the groups in the level of RF and A-CCP, ANA and the presence of HLA-B27, as well as in total cholesterol, LDL-cholesterol, glucose as risk factors for atherosclerosis (all p> 0.05). Patients with active disease had lower BMD in femoral neck and in ultradistal forearm area (all p <0.05). There were no difference in the the appointment of the IBT in doth groups. However, patients with remission more often did not receive GC in history (p <0.001) and at the time of examination (p <0.001), which is explained by less activity in the onset of the disease (p <0.05). Both groups did not differ in either the duration of the DMARD therapy, nor on the doses of methotrexate and sulfosalazine. Of the 53 patients with RF(+)/RF(-) polyarthritis - the most prognostically unfavorable variant of JRA, had arthritis > 3 joints (p <0.01), symmetrical arthritis (p <0.05), higher ESR ( p <0,05) compared patients with remission, and the absence of differences in the levels of CRP and JADAS. Conclusions. Patients with JRA in adulthood in 82.1% continue to have an active disease of varying degrees. The negative influence of the active disease on the BMD is found, mainly in the area of ​​femoral neck and ultradistal forearm in adult patients with active JRA compared with patients in remission. The significant influence of active disease in adulthood on the quality of life according to the SF-36 questionnaire was determined such as physical well-being, physical, role and social functioning, bodily pain, general health, and mental health compared with the group of patients in remission. An increase level of depression was found by PHQ-9 questionnaire in the I group compared to II group, although they did not differ in the level of Alexithymia. Patients who achieved remission compared with patients with active polyarthritis, were less likely to take GC in adulthood and reseived a higher dose of methotrexate.

Sign in / Sign up

Export Citation Format

Share Document